Literature DB >> 22847298

Altered expression of TNFSF4 and TRAF2 mRNAs in peripheral blood mononuclear cells in patients with systemic lupus erythematosus: association with atherosclerotic symptoms and lupus nephritis.

Peyman Rajabi1, Mahsa Alaee, Kazem Mousavizadeh, Ali Samadikuchaksaraei.   

Abstract

OBJECTIVES: This study compares the expression levels of tumor necrosis factor ligand superfamily member 4 (TNFSF4) and TNF-R-associated factor 2 (TRAF2) mRNAs in peripheral blood mononuclear cells (PBMCs) of patients with systemic lupus erythematosus (SLE) against healthy controls. The association of SLE disease activity index (SLEDAI) and clinical features of SLE with altered expression levels of TNFSF4 and TRAF2 mRNAs were also evaluated.
DESIGN: We used real-time reverse transcription polymerase chain reaction to measure TNFSF4 and TRAF2 mRNAs expression levels in peripheral blood mononuclear cells of 57 SLE patients and 57 healthy controls.
RESULTS: The expression level of TNFSF4 mRNA was significantly higher in SLE patients than in the control group. Overexpression of TNFSF4 was correlated with arthritis, atherosclerosis and lupus nephritis. TRAF2 mRNA was underexpressed in PBMCs of SLE patients, and its lower expression was associated with atherosclerosis and lupus nephritis. The altered expression levels of TNFSF4 and TRAF2 mRNAs was significantly correlated with SLEDAI.
CONCLUSION: Our results suggest that changes in the expression levels of TNFSF4 and TRAF2 mRNAs may significantly correlate with the pathogenesis of SLE, the disease activity and different clinical features of lupus, particularly lupus nephritis, atherosclerosis and arthritis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22847298     DOI: 10.1007/s00011-012-0535-6

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  53 in total

1.  Cooperation between TNF receptor-associated factors 1 and 2 in CD40 signaling.

Authors:  Ping Xie; Bruce S Hostager; Melissa E Munroe; Carissa R Moore; Gail A Bishop
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

2.  Essential role of OX40L on B cells in persistent alloantibody production following repeated alloimmunizations.

Authors:  Hiroshi Kato; Hidefumi Kojima; Naoto Ishii; Hidenori Hase; Yutaka Imai; Takashi Fujibayashi; Kazuo Sugamura; Testuji Kobata
Journal:  J Clin Immunol       Date:  2004-05       Impact factor: 8.317

3.  Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus.

Authors:  Corinna E Weckerle; Beverly S Franek; Jennifer A Kelly; Marissa Kumabe; Rachel A Mikolaitis; Stephanie L Green; Tammy O Utset; Meenakshi Jolly; Judith A James; John B Harley; Timothy B Niewold
Journal:  Arthritis Rheum       Date:  2011-04

4.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

5.  Signaling through OX40 (CD134) breaks peripheral T-cell tolerance.

Authors:  P Bansal-Pakala; A G Jember; M Croft
Journal:  Nat Med       Date:  2001-08       Impact factor: 53.440

6.  CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice.

Authors:  Juergen Foell; Simona Strahotin; Shawn P O'Neil; Megan M McCausland; Carolyn Suwyn; Michael Haber; Praveen N Chander; Abhijit S Bapat; Xiao-Jie Yan; Nicholas Chiorazzi; Michael K Hoffmann; Robert S Mittler
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

7.  Prevention of diabetes in NOD mice at a late stage by targeting OX40/OX40 ligand interactions.

Authors:  Syamasundar V Pakala; Pratima Bansal-Pakala; Beth S Halteman; Michael Croft
Journal:  Eur J Immunol       Date:  2004-11       Impact factor: 5.532

Review 8.  Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies.

Authors:  Isaac T W Harley; Kenneth M Kaufman; Carl D Langefeld; John B Harley; Jennifer A Kelly
Journal:  Nat Rev Genet       Date:  2009-05       Impact factor: 53.242

9.  Plasmacytoid dendritic cells regulate Th cell responses through OX40 ligand and type I IFNs.

Authors:  Tomoki Ito; Ryuichi Amakawa; Muneo Inaba; Toshiyuki Hori; Maiko Ota; Kengo Nakamura; Masashi Takebayashi; Michihiko Miyaji; Tomoo Yoshimura; Kayo Inaba; Shirou Fukuhara
Journal:  J Immunol       Date:  2004-04-01       Impact factor: 5.422

10.  TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand.

Authors:  Tomoki Ito; Yui-Hsi Wang; Omar Duramad; Toshiyuki Hori; Guy J Delespesse; Norihiko Watanabe; F Xiao-Feng Qin; Zhengbin Yao; Wei Cao; Yong-Jun Liu
Journal:  J Exp Med       Date:  2005-11-07       Impact factor: 14.307

View more
  12 in total

Review 1.  Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis.

Authors:  Chandra Mohan; Chaim Putterman
Journal:  Nat Rev Nephrol       Date:  2015-03-31       Impact factor: 28.314

2.  TRAF5-mediated Lys-63-linked Polyubiquitination Plays an Essential Role in Positive Regulation of RORγt in Promoting IL-17A Expression.

Authors:  Xiuwen Wang; Jing Yang; Lei Han; Kaixia Zhao; Qingsi Wu; Liming Bao; Zhiyuan Li; Ling Lv; Bin Li
Journal:  J Biol Chem       Date:  2015-10-09       Impact factor: 5.157

3.  TRAF molecules in inflammation and inflammatory diseases.

Authors:  Almin I Lalani; Sining Zhu; Samantha Gokhale; Juan Jin; Ping Xie
Journal:  Curr Pharmacol Rep       Date:  2017-12-20

Review 4.  Structural feature of TRAFs, their related human diseases and therapeutic intervention.

Authors:  Hyun Ho Park
Journal:  Arch Pharm Res       Date:  2021-05-10       Impact factor: 4.946

5.  TRAF molecules in cell signaling and in human diseases.

Authors:  Ping Xie
Journal:  J Mol Signal       Date:  2013-06-13

6.  Systemic Lupus Erythematosus: Old and New Susceptibility Genes versus Clinical Manifestations.

Authors:  De Azevêdo Silva J; Addobbati C; Sandrin-Garcia P; Crovella S
Journal:  Curr Genomics       Date:  2014-02       Impact factor: 2.236

7.  Increased Expressions of OX40 and OX40 Ligand in Patients with Primary Immune Thrombocytopenia.

Authors:  Dawei Cui; Yan Lv; Xinwang Yuan; Guoxiang Ruan; Yu Zhang; Cuilin Yan; Dandan Xu; Mengen Lv; Yun Mao; Jianping Cao; Jie Jin; Jue Xie
Journal:  J Immunol Res       Date:  2019-03-03       Impact factor: 4.818

Review 8.  OX40, OX40L and Autoimmunity: a Comprehensive Review.

Authors:  Gwilym J Webb; Gideon M Hirschfield; Peter J L Lane
Journal:  Clin Rev Allergy Immunol       Date:  2016-06       Impact factor: 8.667

9.  Targeted genomic analysis reveals widespread autoimmune disease association with regulatory variants in the TNF superfamily cytokine signalling network.

Authors:  Arianne C Richard; James E Peters; James C Lee; Golnaz Vahedi; Alejandro A Schäffer; Richard M Siegel; Paul A Lyons; Kenneth G C Smith
Journal:  Genome Med       Date:  2016-07-19       Impact factor: 11.117

10.  NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus.

Authors:  Hans D Brightbill; Eric Suto; Nicole Blaquiere; Nandhini Ramamoorthi; Swathi Sujatha-Bhaskar; Emily B Gogol; Georgette M Castanedo; Benjamin T Jackson; Youngsu C Kwon; Susan Haller; Justin Lesch; Karin Bents; Christine Everett; Pawan Bir Kohli; Sandra Linge; Laura Christian; Kathy Barrett; Allan Jaochico; Leonid M Berezhkovskiy; Peter W Fan; Zora Modrusan; Kelli Veliz; Michael J Townsend; Jason DeVoss; Adam R Johnson; Robert Godemann; Wyne P Lee; Cary D Austin; Brent S McKenzie; Jason A Hackney; James J Crawford; Steven T Staben; Moulay H Alaoui Ismaili; Lawren C Wu; Nico Ghilardi
Journal:  Nat Commun       Date:  2018-01-12       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.